The best surgical strategy in patients with left main stem disease  by Hajj-Chahine, Jamil et al.
Letters to the EditorAwordof caution, however, is exem-
plified by one of our patients who had
proven adenocarcinoma of the right
lung and a positron emission tomo-
graphic scan that demonstrated
bilateral hilar and mediastinal uptake
suggestive of nodal metastasis. EBUS
biopsy of both the right and left paratra-
cheal and hilar areas demonstrated ma-
lignant cells when a biopsy was
acquired from the right side. On the ba-
sis of this finding, the patient was rec-
ommended not to have additional
interventional therapy, but rather to
have a regimen of chemotherapy and
radiotherapy. When we were consulted
for a second opinion. On review of her
studies, it was our feeling that she did
not have strong evidence of metastatic
disease. Surgical intervention with up-
per lobectomy and removal of 18 hilar
and mediastinal lymph nodes revealed
no positive nodal metastasis on micro-
scopic pathologic review.
On retrospective review of the orig-
inal EBUS study, there were both ma-
lignant cells and lymphoid cells
within the specimen. Our feeling, ret-
rospectively, was that a false-positive
report suggesting metastatic disease
resulted from the needle passing
through the node and into the lung,
thus obtaining pulmonary carcinoma
cells compared with nodal carcinoma
cells. This may lead to a potential mis-
diagnosis and misstaging, resulting
from a false-positive result of meta-
static carcinoma to the lymph nodes,
and a nonoperative or different thera-
peutic recommendation.
Raymond A. Dieter, Jr, MD
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To the Editor:
We read with great interest the arti-
cle by Murzi and colleagues1 regard-
ing the best surgical management in
coronary artery disease patients with
left main stem disease undergoing sur-
gical revascularization. The authors
present a high quality observational
study comparing off-pump coronary
artery bypass grafting (CABG) with
on-pump CABG, in a large cohort of
consecutive patients with left main
stem disease over a period of 15 years.
Actually, 2 randomized studies had
already addressed this question: the
Veterans Affairs Randomized On/Off
Bypass (ROOBY) trial2 and the
CABG Off or On Pump Revasculari-
zation Study (CORONARY) trial.3
The CORONARY trial3 is the larg-
est multinational, prospective, ran-
domized trial to date, involving
4,752 patients, conducted in 19 coun-
tries at 79 centers. More than 20%
of enrolled patients showed signifi-
cant left main stem disease. At 30
days after randomization, there was
no significant difference between
off-pump and on-pump CABG
with respect to the rate of death,
nonfatal myocardial infarction, non-
fatal stroke, or renal failure requiring
dialysis. Subgroup analyses showed
that there was no significant differ-
ence concerning the coprimary out-
come in patients (n ¼ 1001) with
left main stem disease at 1 month af-
ter randomization (off-pump n ¼ 514
patients, on-pump n ¼ 487; hazard
ratio, 0.80; 95% confidence interval,
0.55-1.16; P ¼ .24). The sure-to-
be-forthcoming midterm and long-
term primary outcomes results will
influence the interpretation of the
CORONARY trial.
The ROOBY trial,2 which involved
2,203 male patients in 18 Veterans
Affairs medical centers demonstrated
no advantage for off-pump CABG
either at 30 days or at 1 year after
surgery. There was no significantof Thoracic and Cardiovascular Surgerdifference between the 2 cohorts
concerning the primary short-term
(ie, before discharge or within 30
days after surgery) composite out-
come of death or postoperative major
morbidity (ie, reoperation, new me-
chanical support, cardiac arrest,
coma, stroke, or renal failure requir-
ing dialysis). However, at 1-year
follow-up, patients in the beating-
heart technique group experienced
worse composite outcomes (ie, death
from any cause, repeat revasculariza-
tion procedure, or nonfatal myocar-
dial infarction) than did patients in
the on-pump group. The rate of graft
patency was significantly lower in the
off-pump group than in the on-pump
group (82.6% vs 87.8%; P < .01)
at 1 year and this accounted for
most of the difference in late com-
posite outcomes between the 2
groups. Notably, Shroyer et al2 state
that their ROOBY trial conclusions
can be generalized to subgroups of
high risk candidates, among them pa-
tients with left stem main disease.
We have only 1 question for Murzi
and colleagues1 regarding their surgi-
cal management in the off-pump
group: Might the 0% stroke result
found in the off-pump CABG group
have been the result of using total arte-
rial revascularization and aortic ‘‘no-
touch’’ techniques? Both of those
methods decrease significantly the
incidence of stroke after CABG,
particularly in patients with aortic
atherosclerosis.
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We thank Chahine and colleagues
for their letter in response to our arti-
cle discussing on-pump and off-
pump coronary artery bypass grafting
in patients with left main stem dis-
ease.1 We never claimed that off-
pump coronary artery bypass surgery
is the best strategy for patients with
left main disease. Our conclusion
was that ‘‘off-pump coronary artery
surgery in patients with left main
stem disease is a safe procedure that
will reduce morbidity and mortality
and similar long-term survival com-
pared with conventional on-pump
revascularization.’’
We are aware of the results of the 2
recent randomized studies referred to
in the letter. The Coronary Artery By-
pass Grafting Off or On Pump Revas-
cularization trial2 did not demonstrate
any substantial difference between the
2 techniques, and the study concluded
that ‘‘There was no significant differ-
ence between off-pump and on-pump
CABG with respect to the 30-day
rate of death, myocardial infarction,
stroke, or renal failure requiring dialy-
sis.’’ Those authors go on to say, ‘‘The
use of off-pump CABG resulted in
reduced rates of transfusion, reopera-
tion for perioperative bleeding, res-
piratory complications, and acute
kidney injury but also resulted in an
increased risk of early revasculariza-
tion.’’2 However, investigators in the
Veterans Affairs Randomized On/Off
Bypass trial3 concluded that the
results of surgeries performed off-
pump were inferior to conventional
on-pump coronary artery bypass graft
surgery. That study, as pointed out in1274 The Journal of Thoracic anda recent editorial,4 had several major
limitations. More than 70% of eligi-
ble patients (ie, scheduled for urgent
or elective coronary artery bypass
grafting) were excluded because of
clinical reservations of the surgical
team or small target vessels. This sug-
gests inexperience on the part of sur-
geons in the trial, who were required
to have performed just 20 off-pump
coronary artery bypass procedures
(OPCAB) to participate. Conversion
to on-pump coronary artery bypass,
which is known to increase morbidity
and mortality, occurred in>12% of
cases, much greater than the 1% to
3% reported by centers specializing
in OPCAB. In the OPCAB group,
>50% of patients received red blood
cell transfusions, which contrasts
with the 30% in previous randomized
trials. Finally, only a small minority of
the studied population were high-risk
patients, a group more likely to benefit
from OPCAB.
At the Bristol Heart Institute we
have been performing OPCAB sur-
gery for>17 years. We are a high vol-
ume center, with OPCAB accounting
for 70% of all coronary procedures.
We recognize that OPCAB surgery is
a technically demanding procedure
that should be performed in a high
volume center to obtain optimal out-
come. We think that OPCAB is a tech-
nique for the many and not the few
(both surgeons and patients) but only
with structured training and supervi-
sion in the right environment.4
Finally, with regard to the specific
question on the incidence of stroke, in
our article we reported a similar 0.4%
incidence of transient cerebrovascular
accident (CVA) in both groups and
0% and 0.9% of permanent CVA in
the off-pump and on-pump groups, re-
spectively. With off-pump procedures
it is possible to minimize manipulation
of the aorta because there is no require-
ment for cannulation when performing
total arterial revascularization. How-
ever, in our series a majority of patients
also receivedvein grafts thatwere anas-
tomosed to the ascending aorta usingCardiovascular Surgery c November 20a side bite exclusion clamp. The inci-
dence of CVA was low regardless if
patients were operated on using the
on-pump or off-pump technique. We
have no reason to believe that this infor-
mation is inaccurate given that it was
obtained fromour institution’s prospec-
tively collected database. Permanent
CVA is a clearly defined event that is
most unlikely to have been missed by
our clinicians.
Gianni D. Angelini, MD
Michele Murzi, MD
Bristol Heart Institute
University of Bristol
Bristol, United Kingdom
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PLATELET REACTIVITY IN
CORONARYARTERY BYPASS
GRAFTING PATIENTS
SUGGESTS THE NEED FOR
PERIOPERATIVE PLATELET
FUNCTION TESTING
To the Editor:
With great interestwe have read a re-
cent article from Deja and colleagues1
on preoperative aspirin in an elective
coronary artery bypass grafting popu-
lation. The authors conducted a sin-
gle-center, double-blind, randomized
trial comparing its effects to placebo.
The primary endpoints were more
than 750 mL of bleeding during the
first 12 hours postoperatively and12
